Information Provided By: 
Fly News Breaks for February 13, 2018
ABMD
Feb 13, 2018 | 11:04 EDT
Piper Jaffray analyst Matt O'Brien kept an Overweight rating on Abiomed after the company announced the receipt of FDA approval for an expanded indication of its PMA for Impella to include cardiomyopathy. O'Brien sees this as "a nod from the FDA on total heart recovery," and also sees augmented growth as Abiomed can market Impella on label for this indication. O'Brien recommended starting or building positions in the stock.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
